An overview of the molecular landscape of GIST cases showed KIT mutations in 74.8% of the cases, PDGFRA mutations in 14.8% of the cases, and 10.4% of the cases were KIT/PDGFRA wildtype, which was in line with other studies [15, 39–45]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.